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Pediatric critical care is a relatively new
field, tracing its origins to the polio epi-
demics that killed large numbers of chil-
dren, birthed by ongoing efforts in pedi-
atric anesthesiology and neonatology, and
nourished by parallel advances in pedi-
atric pulmonology, cardiology, nephrology,
adult critical care, general, cardiothoracic,
neurosurgery, or other fields. Although
not many pediatric intensive care units
(PICUs) existed before 1980 (Table 1) (1–
3), they now occupy a central position in
the care of all hospitalized children and
in their improved survival from all types
of medical/surgical conditions. Despite an
overwhelmingly clinical focus and lim-
ited avenues for disseminating research,
the numbers of PICU-related publica-
tions have increased steadily over the past
20 years, currently hovering around 5000
reports per year.
Pediatric Critical Care, a section in the
journal Frontiers in Pediatrics, seeks to
disseminate the highest quality scholarly
activity in this field, thus closing gaps
between clinical practices and the high-
level evidence supporting these practices.
The four grand challenges include:
1. Fostering innovation in clinical medi-
cine and technology.
2. Translating basic research into new
diagnostic/therapeutic tools.
3. Defining short-term and long-term out-
comes.
4. Commitments to research, training, and
access to care.
FOSTERING INNOVATION IN CLINICAL
MEDICINE AND TECHNOLOGY
Recent discoveries elucidating the mecha-
nisms of critical illness led to substantial
advancements in pediatric critical care (1,
2), dramatically improving the outcomes
of life-threatening illnesses or injuries in
childhood. But now is not the time to
rest on our laurels! Accelerating progress
in multiple fields of biomedical and
pharmaceutical sciences, imaging and
computational sciences, and biomaterials
and bioengineering sciences must be cou-
pled with an unrelenting pursuit of basic
science and clinical research to translate
these discoveries into improving the care
of very sick children. Pediatric intensivists
must remain at the forefront of developing
or evaluating novel technologies because
of their unique perspectives gained from
treating the whole patient and family;
providing care at the end of life; and expo-
sure to the entire ranges of demographics,
medical/surgical conditions, and societal
subgroups. Surveying the technological
advances available for clinical application
is impossible but two examples, regenera-
tive medicine and personalized medicine,
are mentioned here.
Innovation is rampant in the interdis-
ciplinary fields of stem-cell therapy and
regenerative medicine (4–8), which will
significantly impact future treatments for
organ failures, metabolic disorders, degen-
erative conditions, or the long-term seque-
lae of critical illness. Repair, replacement,
or regeneration of various tissues or organs
in critical illness is possible but com-
plex (5–7), perhaps using combinations of
several approaches including pluripotent
stem cells, soluble molecules, genetic/tissue
engineering, or advanced cell therapies
(9–12). Using autologous bone marrow
stem cells to restore cardiac myocytes (13–
16) or neural stem cells for traumatic
or hypoxic brain injury (17–19) will not
only save lives but also considerably reduce
the costs and side effects of managing
chronic organ failure or neurodevelop-
mental sequelae.
Innovative advances in developmental
biology and genetics/genomics will spawn
“targeted” or personalized therapies for
critical illness (20–22). The current explo-
sion in genetic knowledge will help pedi-
atric intensivists choose the best treat-
ment among existing medicines based on
a patient’s genetic, demographic, and envi-
ronmental factors (21). Genetic adreno-
ceptor variants may dictate our choice
of vasopressors and inotropes (23–25) or
bronchodilators (26, 27), whereas opioid
receptor variants may drive our choice of
analgesics (28, 29). Pediatric intensivists
will also have access to genetic tests reveal-
ing host susceptibility to specific infections,
organ dysfunctions, or non-communicable
diseases (30, 31). Studies on the human
microbiome may help prevent sepsis in
immune-compromised children (32) or
tracheal infections in chronically ventilated
patients (33).
Innovation will not come solely from
these areas. Unique tools from clinical
informatics can abstract patient data from
electronic medical records and link these
data with administrative, insurance, edu-
cational, or multi-institutional databases –
providing the statistical power to address
previously unanswerable questions (34,
35). Current researchers have the abil-
ity to cross-link genomic data with large
clinical databases to generate genotype–
phenotype correlations, thus revealing
novel physiological pathways or therapeu-
tic targets. Biopharmaceuticals designed
by coupling “-omics” with combinator-
ial chemistry will allow them to iden-
tify previously unknown therapeutic tar-
gets. Implantable devices like drug-eluting
stents, biodegradable polymers, or other
devices will also play an important role in
improving the clinical outcomes of PICU
patients.
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Table 1 | Early history of pediatric ICUs.
Year Medical director Institution
1955 Dr. Göran Hagland Göteburg Children’s Hospital, Göteburg, Sweden
1961 Dr. Hans Feychting St. Göran’s Hospital, Stockholm, Sweden
1963 Dr. J. B. Joly Hopital St. Vincent de Paul, Paris, France
Dr. I. H. McDonald Royal Children’s Hospital, Melbourne, Australia
1964 Dr. G. Jackson Rees Alder Hey Children’s Hospital, Liverpool, UK
1967 Dr. John J. Downes Children’s Hospital of Philadelphia, Philadelphia, USA
1969 Dr. Stephan Kampschulte Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
Dr. James Gilman Yale-New Haven Medical Center, New Haven, CT, USA
Dr. Donald Clogg Montreal Children’s Hospital, Montreal, Canada
1971 Dr. I. David Todres Massachusetts General Hospital, Boston, MA, USA
Dr. Alan Conn Hospital for Sick Children, Toronto, Canada
1976 Dr. Peter Holbrook Children’s National Medical Center, Washington DC, USA
Dr. Mark Rogers Johns Hopkins University Hospital, Baltimore, MD, USA
1980 Dr. Robert Crone Children’s Hospital Medical Center, Boston, MA, USA
Dr. Gregory Stidham Le Bonheur Children’s Hospital, Memphis, TN, USA
TRANSLATING BASIC RESEARCH INTO
NEW DIAGNOSTIC/THERAPEUTIC
TOOLS
The route from laboratory research to
newer therapeutics or diagnostics is long,
difficult, and often fraught with regula-
tory mishaps or unforeseen obstacles (36–
38). Examples, where obvious therapeu-
tic targets with excellent pre-clinical data
did not translate into safe/effective ther-
apies (39–41), are well-known in critical
care, such as immune-based therapies tar-
geting the systemic inflammatory response
syndrome or sepsis (42). These disap-
pointments probably resulted from inapt
extrapolations of mouse immunology to
humans (43), reductionist biological prin-
ciples (44), or inadequate consideration
given to the multi-layered and intricately
networked human immune system (45–
47). Innovative leads to address the prob-
lems of integration may come from the Vir-
tual Physiological Human project, which
establishes a technological framework for
studying the human body as a single com-
plex system (48, 49). Large collaborative
in silico models will help us to assem-
ble and investigate the entire human phys-
iome, with greater chances for drug discov-
ery leading to therapeutic success than the
experimental approaches used previously.
Translational research places greater
emphasis on understanding the molecular
underpinnings of pediatric critical illness
and developing biomarkers with diagnos-
tic/therapeutic relevance. Recent research
shows biomarkers associated with specific
organ dysfunctions in children, e.g., acute
kidney injury (50, 51). Specific biomark-
ers for early organ injury can detect certain
diseases at their earliest stages, before the
onset of clinical signs or symptoms (51–
53). Initiating supportive or therapeutic
interventions when these diseases are easily
treatable or preventable will improve clini-
cal outcomes. Identifying sensitive and spe-
cific biomarkers will allow diagnosis, treat-
ment, monitoring, and prevention guided
by the patient’s molecular signals. Novel
biomarkers built into clinical trials can
serve as surrogate outcomes or predict the
patient’s response to therapy.
Given the current environment of less
research funding, greater regulatory hur-
dles, larger clinical studies, and high legal
liability, most pharmaceutical companies
are reluctant to develop new therapeu-
tics, particularly for a niche market like
children. This is a “Grand Challenge” in
itself, but there is hope on the hori-
zon. In an unprecedented move, 10 large
drug companies and 7 non-profit organi-
zations teamed up with National Institutes
of Health (NIH) to develop drugs treat-
ing Alzheimer’s disease, diabetes, lupus,
or rheumatoid arthritis (54). Such part-
nerships can be formed to tackle the
widely prevalent life-threatening diseases
like viral bronchiolitis or sepsis in children.
To make this happen, however, pediatric
intensivists must come up with visionary
goals, eloquently articulate them to mul-
tiple stakeholders in society, industry, and
government, and then deliver excellence in
implementing the proposed approaches to
tackle these conditions.
DEFINING SHORT-TERM AND
LONG-TERM OUTCOMES
Outcomes research relied on blunt instru-
ments like mortality and morbidity, com-
plications or secondary organ failures, or
process outcomes like the length of ICU
stay or hospital stay, direct or indirect costs,
or quality-of-life parameters. Few studies
have focused on measuring other relevant
clinical outcomes to provide a more fine-
grained assessment of patients’ response to
therapy. Recently, however, newer sources
of funding have stimulated greater inter-
est in patient-centered outcomes, func-
tional outcomes, technology/resource uti-
lization, or behavioral and neurodevelop-
mental outcomes.
Pediatric intensivists must define the
most suitable outcomes to test the pri-
mary or secondary hypotheses generated
in their research, possibly based on physio-
logical (e.g., heart rate variability, micro-
circulatory flow), molecular [e.g., glyco-
protein KL-6 for ARDS (55), neutrophil
gelatinase-associated lipocalin (NGAL) for
kidney injury (51), shed CD163 for organ
dysfunction (56)], or imaging biomark-
ers [e.g., apparent diffusion coefficient
(ADC) using diffusion tensor imaging
(57), oxygen extraction fraction (OEF)
using positron emission tomography (58)].
Newer end-points can also come from
clinical outcomes research, using newer
methodologies based on comparative effec-
tiveness, quality improvement, patient-
centered outcomes, or population health
research. The Patient-Centered Outcomes
Research Institute has helped to define
objective measures for patient-centered
outcomes, such as continuity or satisfac-
tion with care, decisional knowledge, con-
flict, or regret (59). These novel parame-
ters must be included in classical study
designs testing interventions in critically ill
children.
Pediatric intensive care, like any other
complex, high hazard enterprise (e.g., avi-
ation) was identified as an environment
where many adverse events occurred due
to human errors (60–62). Investigations
to reduce drug-related errors attributed to
the “human factor” included, for example,
computerized order-entry (63, 64), direct
observation (65), or 24/7 availability of
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clinical pharmacists (66). However, iso-
lated or piecemeal approaches may have
a limited or short-lived effect in reduc-
ing human errors unless a safety-based
culture is created in the entire hospital.
Although initially resource expensive, this
multifaceted approach leads to substantial
reductions in serious adverse events, pre-
ventable harm, or hospital mortality, with
some improvements in the safety culture
(67). Researchers should explore the possi-
bilities to improve future outcomes in the
PICU using quality improvement science
to prevent human errors (68).
Long-term functional or psychological
outcomes following PICU admission were
neglected in many previous studies in chil-
dren. Examples from cancer and congenital
heart surgery have showed the importance
of evaluating long-term clinical outcomes
(69–71), examining the functional status
of children in their home, school, or hos-
pital environment (72). Other long-term
outcome measures may include neurode-
velopmental or other assessments, but
these methods are time consuming, apply
to narrow age ranges, and may require
specialized training. Newer measures must
be objective, relevant, and measure what
they are designed for with high sensitiv-
ity, specificity, and accuracy, while having
strong psychometric properties. The use
of disease-based patient registries (73),
smart-phone technology, internet access,
and social media will allow us to assess
long-term clinical outcomes like never
before (74, 75). The challenge is to develop
innovative outcome measures using these
tools to effectively assess the long-term
consequences of critical illness or PICU
therapies in children (76).
COMMITMENTS TO RESEARCH,
TRAINING, AND ACCESS TO CARE
Drug discovery or device development was
previously funded by large investments
from industry. This paradigm is changing,
with increasing costs of drug development,
augmented risks of failure in a difficult
regulatory environment, unfamiliar drug
targets, and increased legal liability, which
have reduced the incentives to develop
newer agents. Increasingly, biotech or
other startup companies with low overhead
costs and limited liability are developing
drugs/devices, using R&D funds from
federal granting agencies, philanthropy,
crowdsourcing, or other resources (77,
78). To drive their research agenda, pedi-
atric intensivists must actively collaborate
with these companies and their low-cost
efforts to test new products. The onus
for validating new targets and translating
basic science discoveries into commercially
viable products is shifting increasingly
from industry to academia (77). Acade-
mic faculty must forge mutually beneficial
partnerships with the biotech industry, to
advance their discoveries into new drugs
for critically ill children. Early career inves-
tigators can develop innovative ways to
collaborate with industry, by obtaining
specialized molecules or reagents, bioengi-
neered animals, or advanced training at
these startup companies.
The pipeline of creative innovators in
pediatric critical care will depend on the
type of trainees we attract and the research
training we offer; both factors are some-
what interdependent (79, 80). The chal-
lenge is to create an environment that
fosters the curiosity, drive, and ambitions
of trainees in pediatric critical care. Few
departments have created an ecosystem
that fosters consistent and sustained suc-
cess in training new clinician scientists
(Figure 1). Without wider commitment,
dedicated time, and resources for research,
the future growth of our specialty will be
stunted and impoverished (79, 81). Pro-
grams such as the NIH-funded Pediatric
Critical Care Scientist Development Pro-
gram or training grants held by pediatric
intensivists at other institutions provide
important resources. Commitment to a
clinician scientist’s career requires intense
focus, strong mentorship, and opportuni-
ties for scientific growth even after training
(82, 83). Trainees suited for health services
or clinical research, educational research,
or other scholarly activities can also pro-
vide valuable resources to the specialty.
A shortage of pediatric intensivists exists
even in developed countries, with limited
coverage in rural or remote areas. Region-
alized PICU care increases coverage and
controls costs, although for-profit hospi-
tals often set up PICUs because they sup-
port a variety of other pediatric programs
and services. Deficits in services and infra-
structure for PICU care are more acute
and widespread in resource-poor nations
or international areas with armed con-
flict. Ensuring that all critically ill children
get access to high-quality multidisciplinary
intensive care is a huge challenge! Advances
in telemedicine and transport medicine
are now extending pediatric intensive care
to some remote areas (84–86). Remote
access to ICU monitors, real-time imaging,
live video stream, and electronic medical
records via high-speed internet connec-
tions allow pediatric intensivists to par-
ticipate in the care of children located
remotely (85, 86). Administrative hurdles
in terms of medical licensing, patient pri-
vacy, malpractice liability, insurance cov-
erage, and reimbursement procedures still
need to be overcome in some healthcare
markets (87). However, the clinical out-
comes of remotely managed patients have
not been reported, whereas recent studies
show that patients requiring resuscitation
or mechanical ventilation had improved
outcomes when pediatric intensivists pro-
vided in-house coverage (88–90).
Research and policy changes to over-
come these obstacles, together with alter-
ations in clinical attitudes, approaches,
and outcomes, will provide a rich milieu
for research in pediatric critical care
knowledge exchange and implementa-
tion science (91). Implementation science
investigates the behaviors of healthcare
professionals, administrators, patients, or
other stakeholders as key variables in the
uptake, adoption, and implementation
of evidence-based interventions (67, 92).
It can address major bottlenecks (social,
behavioral, economic, and management)
that impede the effective implementation
of current evidence, test new approaches
to improve healthcare, or determine causal
relationships between an intervention and
its clinical impact.
CONCLUSION
The cumulative burdens of critical illness
among children in developing and devel-
oped countries give us ample opportunities
for research to prevent death, disability,
and other limitations that keep children
from reaching their full potential. Starting
in this Year of the Horse, to be successful
in preventing or managing critical illnesses
that affect children today, researchers must
harness and drive the four horses of inno-
vation, translation, outcomes, and commit-
ments sketched above. The pages of Pedi-
atric Critical Care are eager to record their
exploits and glory for posterity.
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FIGURE 1 | Research-oriented trainees thrive in a challenging and learning environment. Such an environment inspires, nurtures, and prepares trainees
to devote their entire career in the pursuit of new knowledge in the basic sciences and/or its clinical applications, or other fields of enquiry. This flow-chart
represents the life cycle of such a trainee in a research-oriented department. PCCM, Pediatric Critical Care Medicine; PICU, Pediatric Intensive Care Unit.
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